Overall, the liposomal formulation loaded with peptide vaccine and IDO inhibitor displayed a significant tumor inhibition than individual liposomal components, ensuring the lipo-based combinatorial immunotherapy provides a promising melanoma therapy platform. The gene discussed is IDO1; the disease is melanoma.